CARA News and Press, Cara Therapeutics Inc. From 11/08/21

– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administration (FDA) – – Christopher Posner Appointed Presiden...

Cara Therapeutics (NASDAQ:CARA) is scheduled to announce Q3 earnings results on Monday, November 8th, after market close. The consensus EPS Estimate is -$0.33 and the consensus Revenue Estimate is $11.21M (+20.9% Y/Y). The company posted second-quarter profit that beat Wall Street estimates a...

Biopharmaceutical company Cara Therapeutics (NASDAQ:CARA) has appointed Christopher Posner as its new President and CEO, effective November 9, 2021. Posner, a current member of Cara Therapeutics' Board of Directors, will succeed Derek Chalmers, who will transition to a Senior Advisor role. Pr...

STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...

Investors hungry for stocks that can make big moves in a short amount of time know the biotech industry is the best place to look. A new drug approval, or simply clinical trial results that suggest success can push small-cap stocks through the roof. Recently, Cara Therapeutics ...

STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...

Today, we revisit Cara Therapeutics for the first time since February of this year. The company recently received its first FDA approval for KORSUNA, and the first half of 2022 will see the initial rollout results and likely approval for Europe as well. A full investment analysis ...

STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, presented re...

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...